Bahrain turned into the second nation on the planet to endorse the utilization of the Pfizer/BioNTech Covid immunization in the nation, said the nation’s state news office BNA on Friday.
The state news office announced that the endorsement was given by Bahrain’s National Health Regulatory Authority (NHRA) following an exhaustive examination and audit of the accessible data.
“The approval of the Pfizer/BioNTech vaccine will add a further important layer to the Kingdom’s national COVID-19 response, which has strongly prioritised protecting the health of all citizens and residents during the pandemic,” said the Bahrain’s NHRA CEO Dr Mariam Al Jalahma.
On the other hand, Pfizer Gulf Cluster Lead Lindsey Dietschi was cited by the BNA considering it a “historic moment in the fight against COVID-19”.
Read more: New Pfizer, BioNTech Covid antibody may not be reasonable for Asian countries
“This authorisation is a goal we have been working toward since we first declared that science will win, and we applaud the National Health Regulatory Authority in the kingdom of Bahrain for their ability to conduct a careful assessment and take timely action to help protect the people of Bahrain,” said Dietschi
Last month the kingdom had approved the use of the China’s Sinopharm vaccine for its frontline workers.
UK govt green lights Pfizer-BioNTech vaccine
Earlier this week, the United Kingdom became the first country in the world to approve the use of the Pfizer-BioNTech vaccine with the vaccine expecting to be rolled for use from next week.
According to British newspaper Guardian, the vaccine was approved for emergency use by the Medicines and Healthcare Products Regulatory Authority (MHRA).
‘Vaccine over 90% effective’
Last month, large-scale trials of a coronavirus vaccine candidate produced by Pfizer/BioNTech revealed that it is over 90% effective, said the manufacturer in a statement.
The study showed that people who received two doses as part of the trial saw 90% fewer symptomatic cases of COVID-19 than participants who were given a placebo.
“Today is an extraordinary day for science and mankind. The principal set of results from our stage 3 COVID-19 immunization preliminary gives the underlying proof of our antibody’s capacity to forestall COVID-19,” said Dr Albert Bourla, the Pfizer administrator and CEO.
Read more: Behind Pfizer’s Covid immunization, a downplayed a couple ‘dream team’
The study zeroed in on 94 members out of an absolute number of 43,000 individuals. These members were offered the two-portion antibody and 28 days after they got their first vaccination, remained protected.
“To me, this is the most ideal result,” Ugur Sahin, prime supporter and CEO of BioNTech told the Financial Times.
Pfizer hopes to deliver 50 million immunization dosages in 2020 and up to 1.3 billion portions by 2021.